Efficacy evaluation of lead compounds in relevant disease animal models is pivotal for the preclinical candidate selection in drug discovery. Gentury  has established multiple in vivo animal models to evaluate novel drugs for CNS disorders, cancer, metabolic diseases, inflammation and autoimmune diseases. Each disease model is designed to understand specific aspects of drug property and its mechanism of action. By accessing our comprehensive capability, our customers can advance their drug discovery programs in a time and cost-effective manner.

 CNS

Pain, Alzheimer's disease, Parkinson's disease, Huntington's disease and other behavioral disorders

Oncology

A variety of validated human tumor models (subcutaneous and orthotopic xenografts) for both efficacy and mechanism of action (MOA) studies

Metabolic diseases

Diabetes, dyslipidemia, NASH and obesity

Chronic Liver Diseases

Liver fibrosis/cirrhosis (CCI4, TAA, DMNA and BDL)

Inflammation and autoimmune diseases

Asthma, Chronic Obstructive Pulmonary Disease (COPD), arthritis, topical inflammation, etc.